Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Short Interest UpdateMarket Beat·49 minutes agoMDGL-9.83%
MADRIGAL PHARMACEUTICALS, INC. Q2 2026: Revenue $364.25M, EPS ($1.99) — 10-Q SummaryTradingView·6 hours agoMDGL-9.83%
Madrigal Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 364.3 MEarnings Watch·9 hours agoMDGL-9.83%
4 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·2 days ago, 12:35 PMGILD-1.09%NVO+6.00%
Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to "Strong-Buy" at Wells Fargo & CompanyMarket Beat·2 days ago, 05:30 AMMDGL-9.83%
Madrigal grants inducement equity awards to 10 new hires, sets option strike at $550.25PUBT·Jul 21 at 03:11 PMMDGL-9.83%
Madrigal Pharmaceuticals President, CEO Sold Shares Worth Over $1.3MTradingView·Jul 20 at 08:20 PMMDGL-9.83%
10:01 ETNASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Researchprnewswire·Jul 16 at 09:01 AMMDGL-9.83%NVO+6.00%
Madrigal Pharmaceuticals updates financial calendar with quarterly results release, webcast scheduledPUBT·Jul 16 at 07:07 AMMDGL-9.83%
